Compare Gerdau S.A. Common Stock (GGB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Repligen Corporation Common Stock — how do they compare? Gerdau S.A. Common Stock trades at $5.15 (market cap $9.66B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Gerdau S.A. Common Stock pays a 3.48% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| GGB | RGEN | |
|---|---|---|
Market Cap | $9.66B | $11.14B |
Volume | 9,572,970 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $5.18 | $194.57 |
52-Week Low | $3.25 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.61B | $11.02B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gerdau (GGB) trades at $5.18, up 0.78% with strong technical momentum and bullish moving average signals. The company reported mixed Q2 2026 earnings meeting expectations but missed previous quarters, while showing improved profitability with net income margin expanding to 3.23%. Recent news highlights institutional buying interest and dividend appeal, with the stock approaching its 52-week high of $5.48.
GGB presents a value opportunity with attractive valuation multiples (P/S 0.73, P/B 0.95) and strong analyst support (70% buy ratings). However, recent earnings misses and competitive pressures in Brazilian operations pose execution risks. The improving cash flow trajectory and institutional accumulation suggest potential upside if operational improvements continue.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
